Feature Sucampo sees revenue from three continents by year end By Len Zehr Sucampo Pharmaceuticals (NASDAQ:SCMP) expects to be generating revenue from three continents – North America, Europe and Asia – by the end of 2013 from its two approved prostones products, Amitiza for... March 19, 2013